Synthetic approach to designed chemical structures

Details Synthetic approach to designed chemical structures Synthetic approach to designed chemical structures

2006-04-18

2006-04-18

Patterson, Jr., Charles L. (Department: 1652)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

07030087

ABSTRACT:
This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.

REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott
patent: 5190873 (1993-03-01), Lernhardt et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5786324 (1998-07-01), Gray et al.
patent: 5830860 (1998-11-01), Gray et al.
patent: 5837678 (1998-11-01), Little, II
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854214 (1998-12-01), Little, II
patent: 5856302 (1999-01-01), Ammons et al.
patent: 5955577 (1999-09-01), Mayo
patent: 2002/0146406 (2002-10-01), Mayo
patent: WO 89/01486 (1989-02-01), None
patent: WO 90/09183 (1990-08-01), None
patent: WO 92/09621 (1992-06-01), None
patent: WO 92/09695 (1992-06-01), None
patent: WO 93/05797 (1993-04-01), None
patent: WO 93/23434 (1993-11-01), None
patent: WO 94/17819 (1994-08-01), None
patent: WO 94/18323 (1994-08-01), None
patent: WO 94/20532 (1994-09-01), None
patent: WO 94/25476 (1994-11-01), None
patent: WO 95/00641 (1995-01-01), None
patent: WO 95/01428 (1995-01-01), None
patent: WO 95/02414 (1995-01-01), None
patent: WO 96/31528 (1996-10-01), None
patent: WO 96/37212 (1996-11-01), None
Altieri et al., “Association of Biomolecular Systems via Pulsed Field Gradient NMR Self-Diffusion Measurements,”J. Am. Chem. Soc., 117, 7566-7567 (1995).
Anisowicz et al., “Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells.”Proc. Natl. Acad. Sci. USA, 84, 7188-7192 (1987).
Bangalore et al., “Identification of the Primary Antimicrobial Domains in Human Neutrophil Cathespin G.”J. Biol. Chem., 265(23), 13584-13588.
Battafarano et al., “Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro,”Surgery, 118, 318-324 (1995).
Bax et al., “MLEV-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy,”J. Magnetic Resonance, 65, 355-360 (1985).
Blanco et al., “A short linear peptide that folds into a native stable β-hairpin in aqueous solution.”Structural Biology, 1, 584-590 (1994).
Bone et al., “A second large controlled clinical study of E5. a monoclonal antibody to endoxtoxin: Results of a prospective, multicenter, randomized, controlled trial,”Critical Care Medicine, 23, 994-1005 (1995).
Bottone et al., “Association ofPseudomonas cepaciawith Chronic Granulomatous Disease,”J. Clin. Microbiol., 1(5), 425-428 (1975).
Brown et al., “[8] Chemical Synthesis and Cloning of a Tyrosine tRNA Gene.”Methods in Enzymology, 68, 109-151 (1979).
Bryson et al., “Protein Design: A Hierarchic Approach,”Science, 270, 935-941 (1995).
Campanelli et al., “Azurocidin and a Homologous Serine Protease from Neutrophils—Differential Anticmicrobial and Proteolytic Properties,”J. Clin. Invest., 85, 904-915 (1990).
Cantor et al., “The behavior of biological macromolecules.”Biophysical Chemistry, Part III, 979-1039 (1980).
Capone, “Screening Recombinant Baculovirus PlaquesIn Situwith Antibody Probes,”Gene Anal. Techn., 6, 62-66 (1989).
Casey et al., “Neisseria gonorrhoeaeSurvive Intraleukocytic Oxygen—Independent Antimicrobial Capacities of Anaerobic and Aerobic Granulocytes in the Presence of Pyocin Lethal for Extracellular Gonococci”, Infect. Immun.52:384-389 (1986).
Cody et al., “Protective Anti-lipopolysaccharide Monoclonal Antibodies Inhibit Tumor Necrosis Factor Production,”,J. Surg. Res., 52(4):314-319 (1992).
Dahlberg et al., “A Novel Endotoxin Antagonist Attenuates Tumor Necrosis Factor-α Secretion.”Journal of Surgical Research, 63, 44-48 (1996).
D'Amato et al., “Thalidomide is an Inhibitor of Angiogenesis,”Proc. Natl. Acad. Sci. USA, 91(9):4082-4085 (1994).
Dameron et al., “Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1,”Science, 265:1582-1584 (1994).
Deuel et al., “Amino acid sequence of human platelet factor 4,”Proc. Natl. Acad. Sci. USA, 74, 2256-2258 (1977).
Dintzis et al., “A Comparison of the Immunogenicity of a Pair of Enantiomeric Proteins,”Proteins: Structure, Function, and Genetics, 16(3), 306-308 (1993).
Dugas et al.,Bioorganic Chemistry, Springer-Verlag, New York, NY (1981), Title Page, Copyright Page, Table of Contents, and pp. 54-92.
Dunn et al., “Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis,”Surgery, 98, 283-290 (1985).
Elsbach et al., “Bactericidal/permeability increasing protein and host defense against Gram-negative bacterial and endotoxin,”Curr. Opn. in Imm., 5(1), 103-107 (1993).
Farley et al., “Lipopolysaccharide Structure Determines Ionic and Hydrophobic Binding of a Cationic Antimicrobial Neutrophil Granule Protein,”Infect. Immun., 56, 1589-1592 (1988).
Folkman et al., “Antiogenesis.”J. Biol. Chem., 267, 10931-10934 (1992).
Folkman, “What is the Evidence that Tumors are Angiogenesis Dependent?,”Journal of the National Cancer Institute, 82, 4-6 (1990).
Gabay et al., “Antibiotic proteins of human polymorphonuclear leukocytes,”PNAS USA, 86, 5610-5614 (1989).
Gallin et al., “Recent Advances in Chronic Granulomatous Disease,”Ann. Int. Med., 99, 657-674 (1983).
Gazzano-Santoro et al., “High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide,”Infect. Immun., 60(11), 4754-4761 (1992).
Gibbs et al., “A PFG NMR Experiement for Accurate Diffusion and Flow Studies in the Presence of Eddy Currents”, J. Magnetic Resonance, 93:395-402 (1991).
Gray et al., “Cloning of the cDNA of a Human Neutrophil Bactericidal Protein,”J. Biol. Chem., 264(16), 9505-9509 (1989).
Gray et al., Cystic Fibrosis Foundation Grant No. 2R01-A1-26159 awarded by NIH (1990) (Abstract Only).
Gray, “Metabolic Stimulation and Bactericidal Function of Polymorphonuclear Leukocytes,”J. Retic. Soc., 22(2):87-88 (1977).
Griffioen et al., “Endothelial Intercellular Adhesion Molecule-1 Expression Is Suppressed in Human Malignancies: The Role of Angiogenic Factors.”Cancer Research, 56, 1111-1117 (1996).
Griffioen et al., “Anginex, a designed peptide that inhibits angiogenesis”, (2001)Biochemical Society, 354, 233-242.
Griffioen et al., “Tumor Angiogenesis Is Accompanied by a Decreased Inflammatory Response of Tumor-Associated Endothelium,”Blood, 88(2):667-673 (1996).
Griffioen et al., “Tumor Angiogenesis Is Accompanied by a Decreased Inflammatory Response of Tumor-Associated Endothelium,”Proc. Am. Ass. Cancer Res., 37:55, Abstract No. 380 (1996).
Groenewegen et al., “Supernatants of Human Leukocytes Contain Mediator, Different From Interferon γ. Which Induces Expression of MHC Class II Antigens,”J. Exp. Med., 164:131-143 (1986).
Gupta et al., “A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4,”PNAS USA,92, 7799-7803 (1995).
Hancock, “Alterations in Outer Membrane Permeability.”Ann. Rev. Microbiol., 38, 237-264 (1984).
Harlow et al., Eds.,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988), Title Page. Copyright Page. and Table of Contents.
Hartree,

Affiliated with

Also associated with

Rating

Synthetic approach to designed chemical structures does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic approach to designed chemical structures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic approach to designed chemical structures will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3526142